Karen S. Lynch - 03 May 2023 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Issuer symbol
CVS
Transactions as of
03 May 2023
Net transactions value
+$976,567
Form type
4
Filing time
05 May 2023, 08:27:16 UTC
Previous filing
04 Apr 2023
Next filing
14 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock (By Trust) Purchase $976,567 +14,000 +3.4% $69.75 431,392 03 May 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Appreciation Rights 192,741 03 May 2023 Common Stock 192,741 $45.91 Direct F1
holding CVS Stock Appreciation Rights 93,989 03 May 2023 Common Stock 93,989 $37.91 Direct F2
holding CVS Stock Option 242,408 03 May 2023 Common Stock 242,408 $54.19 Direct F3
holding CVS Stock Option 211,196 03 May 2023 Common Stock 211,196 $58.34 Direct F4, F5
holding CVS Stock Option 224,604 03 May 2023 Common Stock 224,604 $74.30 Direct F6
holding CVS Stock Option 171,517 03 May 2023 Common Stock 171,517 $101.09 Direct F7
holding CVS Stock Option 244,952 03 May 2023 Common Stock 244,952 $74.31 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vest in two substantially equal annual installments beginning on February 17, 2019.
F2 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F3 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F4 The number of shares subject to the option were calculated using a 30-day average price.
F5 Option became exercisable in four equal installments, commencing 4/1/2021.
F6 Option became exercisable in four equal installments, commencing 4/1/2022.
F7 Option became exercisable in four equal installments, commencing 4/1/2023.
F8 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.